Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Intangibles (2016 - 2022)

Historic Intangibles for Ernexa Therapeutics (ERNA) over the last 13 years, with Q1 2022 value amounting to $6.0 million.

  • Ernexa Therapeutics' Intangibles fell 1253.64% to $6.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $6.0 million, marking a year-over-year decrease of 1253.64%. This contributed to the annual value of $6.0 million for FY2020, which is 21279.37% up from last year.
  • Ernexa Therapeutics' Intangibles amounted to $6.0 million in Q1 2022, which was down 1253.64% from $6.9 million recorded in Q3 2021.
  • In the past 5 years, Ernexa Therapeutics' Intangibles registered a high of $6.9 million during Q1 2021, and its lowest value of $1.4 million during Q3 2020.
  • Over the past 5 years, Ernexa Therapeutics' median Intangibles value was $2.3 million (recorded in 2019), while the average stood at $3.5 million.
  • Its Intangibles has fluctuated over the past 5 years, first plummeted by 4329.07% in 2020, then soared by 38309.86% in 2021.
  • Over the past 5 years, Ernexa Therapeutics' Intangibles (Quarter) stood at $2.0 million in 2018, then dropped by 5.1% to $1.9 million in 2019, then surged by 212.79% to $6.0 million in 2020, then grew by 14.52% to $6.9 million in 2021, then dropped by 12.54% to $6.0 million in 2022.
  • Its last three reported values are $6.0 million in Q1 2022, $6.9 million for Q3 2021, and $6.9 million during Q2 2021.